Merger to create a clinical-stage company focused on clinical and commercial development of cytisine, a selective nicotine receptor partial agonist currently in late-stage development for smoking cessation.
Forbes is reporting that the Food and Drug Administration’s approval of 22 new drugs in 2016 (down from 51 in 2015) could have big implications for the future of innovation in the pharmaceutical space. The report notes that research spending is growing, but there are practical difficulties to translate innovation into products as R&D returns decline — and the report suggests overcoming that difficulty could mean rethinking a lot. (Forbes)
The drug’s availability comes a year after the Food and Drug Administration approved it as a follow-on biologic to Lantus, another U-100 long-acting insulin. It has an amino acid sequence identical to that of Lantus.
The act will invest more than $6 billion over seven years to provide funding for various initiatives, including fighting prescription drug abuse, expanding the president’s Precision Medication Initiative and funding the “cancer moonshot,” aimed at finding new and better treatments for cancer.